$TGTX
TG THERAPEUTICS, INC. Stock $tgtx

$tgtx Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000155837023013429 Filed on August 04, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$165.8M	$16.07M	$594.0K
YoY Change	176298.94%	2606.06%	-61.55%
Cost Of Revenue	$3.509M	$1.911M	$23.00K
YoY Change	175350.0%	8208.7%	-84.46%
Gross Profit	$162.3M	$14.16M	$571.0K
YoY Change	176319.57%	2380.39%	-59.13%
Gross Profit Margin	97.88%	88.11%	96.13%
Selling, General & Admin	$32.77M	$30.72M	$12.64M
YoY Change	129.89%	143.04%	-62.85%
% of Gross Profit	20.19%	216.87%	2213.31%
Research & Development	$14.75M	$28.12M	$26.87M
YoY Change	-29.08%	4.64%	-40.11%
% of Gross Profit	9.09%	198.56%	4706.48%
Depreciation & Amortization	$70.00K	$32.00K	$78.00K
YoY Change	-7.89%	-58.97%	18.18%
% of Gross Profit	0.04%	0.23%	13.66%
Operating Expenses	$47.52M	$58.84M	$39.51M
YoY Change	35.56%	48.91%	-50.01%
Operating Profit	$114.8M	-$44.67M	-$38.94M
YoY Change	-428.3%	14.72%	-49.75%
Interest Expense	$3.713M	-$3.627M	-$3.017M
YoY Change	125.3%	20.22%	-285.89%
% of Operating Profit	3.23%
Other Income/Expense, Net	-$854.0K	$691.0K	$1.448M
YoY Change	-0.12%	-52.28%	-244.08%
Pretax Income	$113.9M	-$47.61M	-$40.51M
YoY Change	-418.0%	17.53%	-48.39%
Income Tax	$0.00	$0.00
% Of Pretax Income	0.0%
Net Earnings	$113.9M	-$47.61M	-$40.51M
YoY Change	-418.08%	17.53%	-48.39%
Net Earnings / Revenue	68.71%	-296.19%	-6819.87%
Basic Earnings Per Share	$0.80	-$0.34	-$0.30
Diluted Earnings Per Share	$0.73	-$0.34	-$300.6K
COMMON SHARES
Basic Shares Outstanding	151.0M	149.4M	144.4M
Diluted Shares Outstanding	155.9M	141.5M	134.8M

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$229.2M	$144.9M	$195.7M
YoY Change	30.27%	-25.96%	-55.87%
Cash & Equivalents	$150.9M	$97.01M	$147.1M
Short-Term Investments	$78.30M	$47.90M	$48.64M
Other Short-Term Assets	$12.08M	$11.09M	$6.763M
YoY Change	308.97%	63.95%	129.25%
Inventory	$33.55M	$30.23M
Prepaid Expenses
Receivables	$39.30M	$17.48M	$88.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$319.1M	$208.6M	$202.6M
YoY Change	74.45%	2.97%	-55.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$133.0K	$206.0K	$10.96M
YoY Change	-64.63%	-98.12%	1736.35%
Goodwill	$799.0K	$799.0K
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$36.08M
YoY Change	-100.0%	-100.0%	182.81%
Other Assets	$1.300M	$1.279M	$1.266M
YoY Change	2.44%	1.03%	0.4%
Total Long-Term Assets	$11.95M	$12.28M	$49.11M
YoY Change	-65.82%	-74.99%	86.49%
TOTAL ASSETS
Total Short-Term Assets	$319.1M	$208.6M	$202.6M
Total Long-Term Assets	$11.95M	$12.28M	$49.11M
Total Assets	$331.1M	$220.9M	$251.7M
YoY Change	51.94%	-12.24%	-47.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$39.70M	$62.95M	$37.22M
YoY Change	33.55%	69.1%	-7.47%
Accrued Expenses	$9.800M	$8.153M	$4.362M
YoY Change	65.71%	86.91%	-56.44%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00		$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$57.68M	$72.67M	$43.33M
YoY Change	58.25%	67.72%	-50.51%
LONG-TERM LIABILITIES
Long-Term Debt	$98.91M	$97.70M	$68.95M
YoY Change	41.22%	41.7%
Other Long-Term Liabilities	$9.700M	$10.03M	$10.36M
YoY Change	-11.21%	-3.13%	-3.37%
Total Long-Term Liabilities	$98.91M	$97.70M	$79.31M
YoY Change	41.22%	23.2%	639.85%
TOTAL LIABILITIES
Total Short-Term Liabilities	$57.68M	$72.67M	$43.33M
Total Long-Term Liabilities	$98.91M	$97.70M	$79.31M
Total Liabilities	$166.3M	$180.4M	$122.6M
YoY Change	41.64%	47.11%	24.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.500B	-$1.614B
YoY Change	0.0%
Common Stock	$151.0K	$151.0K
YoY Change	4.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$164.8M	$40.45M	$129.0M
YoY Change
Total Liabilities & Shareholders Equity	$331.1M	$220.9M	$251.7M
YoY Change	51.94%	-12.24%	-47.72%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	$113.9M	-$47.61M	-$40.51M
YoY Change	-418.08%	17.53%	-48.39%
Depreciation, Depletion And Amortization	$70.00K	$32.00K	$78.00K
YoY Change	-7.89%	-58.97%	18.18%
Cash From Operating Activities	$83.71M	-$42.00M	-$49.12M
YoY Change	-342.67%	-14.48%	-18.36%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change	-100.0%		-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$30.23M	$30.50M	$10.38M
YoY Change	912.39%	193.87%	-551.85%
Cash From Investing Activities	-$30.23M	$30.50M	$10.38M
YoY Change	911.04%	193.87%	-518.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	420.0K	47.05M	135.0K
YoY Change	52.73%	34749.63%	-101.89%
NET CHANGE
Cash From Operating Activities	83.71M	-42.00M	-49.12M
Cash From Investing Activities	-30.23M	30.50M	10.38M
Cash From Financing Activities	420.0K	47.05M	135.0K
Net Change In Cash	53.90M	35.54M	-38.60M
YoY Change	-244.85%	-192.08%	-44.7%
FREE CASH FLOW
Cash From Operating Activities	$83.71M	-$42.00M	-$49.12M
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	$83.71M	-$42.00M	-$49.12M
YoY Change	-342.7%	-14.48%	-18.13%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Central Index Key EntityCentralIndexKey	0001001316
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8475000
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1613875000
	us-gaap	Share Based Compensation ShareBasedCompensation	19364000
CY2023Q2	us-gaap	Other Inventory Capitalized Costs OtherInventoryCapitalizedCosts	1146000
	us-gaap	Share Based Compensation ShareBasedCompensation	19364000
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-32639
	dei	Entity Registrant Name EntityRegistrantName	TG THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	36-3898269
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	36-3898269
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3020 Carrington Mill Blvd, Suite 475
	dei	Entity Address City Or Town EntityAddressCityOrTown	Morrisville
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NC
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	27560
	dei	City Area Code CityAreaCode	212
	dei	Local Phone Number LocalPhoneNumber	554-4484
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	TGTX
	dei	Trading Symbol TradingSymbol	TGTX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	150977564
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97009000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102304000
CY2023Q2	us-gaap	Short Term Investments ShortTermInvestments	47896000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	59374000
CY2023Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	17484000
CY2023Q2	us-gaap	Inventory Net InventoryNet	30234000
CY2023Q2	tgtx	Prepaid Research And Development PrepaidResearchAndDevelopment	4863000
CY2022Q4	tgtx	Prepaid Research And Development PrepaidResearchAndDevelopment	4237000
CY2023Q2	us-gaap	Other Assets Current OtherAssetsCurrent	11088000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2359000
CY2023Q2	us-gaap	Assets Current AssetsCurrent	208574000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	168274000
CY2023Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1279000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1273000
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	12404000
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8475000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8888000
CY2023Q2	tgtx	Leasehold Interest LeaseholdInterest	1521000
CY2022Q4	tgtx	Leasehold Interest LeaseholdInterest	1627000
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	206000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	307000
CY2023Q2	us-gaap	Goodwill Goodwill	799000
CY2022Q4	us-gaap	Goodwill Goodwill	799000
CY2023Q2	us-gaap	Assets Assets	220854000
CY2022Q4	us-gaap	Assets Assets	193572000
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	62945000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	42019000
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1569000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1169000
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1512000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1581000
CY2023Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	6641000
CY2022Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	8432000
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	72667000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	53201000
CY2023Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	229000
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	305000
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	97700000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	71135000
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9805000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10344000
CY2023Q2	us-gaap	Liabilities Liabilities	180401000
CY2022Q4	us-gaap	Liabilities Liabilities	134985000
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	150969323
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	146426697
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	150928014
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	146385388
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	151000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	146000
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1654411000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1585708000
CY2023Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	41309
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	41309
CY2023Q2	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	234000
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	234000
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1613875000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1527033000
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	40453000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	58587000
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	220854000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	193572000
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16074000
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	594000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23877000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2610000
CY2023Q2	tgtx	Cost Of Product Revenue CostOfProductRevenue	1911000
CY2022Q2	tgtx	Cost Of Product Revenue CostOfProductRevenue	23000
	tgtx	Cost Of Product Revenue CostOfProductRevenue	2768000
	tgtx	Cost Of Product Revenue CostOfProductRevenue	260000
CY2023Q2	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	5664000
CY2022Q2	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	2328000
	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	7247000
	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	4223000
CY2023Q2	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	22458000
CY2022Q2	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	24546000
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	36744000
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	70693000
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28122000
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26874000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	43991000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	74916000
CY2023Q2	tgtx	Non Cash Compensation Selling General And Administrative Expenses NonCashCompensationSellingGeneralAndAdministrativeExpenses	6877000
CY2022Q2	tgtx	Non Cash Compensation Selling General And Administrative Expenses NonCashCompensationSellingGeneralAndAdministrativeExpenses	-3304000
	tgtx	Non Cash Compensation Selling General And Administrative Expenses NonCashCompensationSellingGeneralAndAdministrativeExpenses	12117000
	tgtx	Non Cash Compensation Selling General And Administrative Expenses NonCashCompensationSellingGeneralAndAdministrativeExpenses	-3077000
CY2023Q2	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	23838000
CY2022Q2	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	15942000
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	46666000
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	36324000
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30715000
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12638000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	58783000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	33247000
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	60748000
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	39535000
	us-gaap	Operating Expenses OperatingExpenses	105542000
	us-gaap	Operating Expenses OperatingExpenses	108423000
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-44674000
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-38941000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-81665000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-105813000
CY2023Q2	us-gaap	Interest Expense InterestExpense	3627000
CY2022Q2	us-gaap	Interest Expense InterestExpense	3017000
	us-gaap	Interest Expense InterestExpense	6471000
	us-gaap	Interest Expense InterestExpense	5681000
CY2023Q2	us-gaap	Other Income OtherIncome	691000
CY2022Q2	us-gaap	Other Income OtherIncome	1448000
	us-gaap	Other Income OtherIncome	1295000
	us-gaap	Other Income OtherIncome	1971000
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2936000
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1569000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5176000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3710000
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-47610000
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-40510000
	us-gaap	Profit Loss ProfitLoss	-86841000
	us-gaap	Profit Loss ProfitLoss	-109523000
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.81
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.81
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	141503738
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	141503738
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	134779904
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	134779904
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	140911295
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	140911295
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	134591250
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	134591250
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	41309
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	237153000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	125000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2121000
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-69013000
CY2022Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	41309
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	170386000
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	135000
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	1000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	-975000
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-40510000
CY2022Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	41309
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	129035000
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	41309
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	58587000
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	363000
CY2023Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	595000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	7120000
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-39232000
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	41309
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	27433000
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	751000
CY2023Q2	tgtx	Offering Costs OfferingCosts	800000
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	46297000
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	13582000
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-47610000
CY2023Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	41309
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	40453000
	us-gaap	Profit Loss ProfitLoss	-86841000
	us-gaap	Profit Loss ProfitLoss	-109523000
	us-gaap	Share Based Compensation ShareBasedCompensation	19364000
	us-gaap	Share Based Compensation ShareBasedCompensation	1146000
	us-gaap	Depreciation Depreciation	100000
	us-gaap	Depreciation Depreciation	154000
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	487000
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	17000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1100000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	922000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	106000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	106000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	990000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1014000
	tgtx	Change In Fair Value Of Notes Payable ChangeInFairValueOfNotesPayable	-261000
	tgtx	Change In Fair Value Of Notes Payable ChangeInFairValueOfNotesPayable	276000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	28896000
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	9316000
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-8054000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	17484000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1301000
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	19136000
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-21355000
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-1187000
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-995000
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1323000
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1740000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-76000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-76000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-101907000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-117805000
	tgtx	Proceeds From Maturities ProceedsFromMaturities	46501000
	tgtx	Proceeds From Maturities ProceedsFromMaturities	38525000
	tgtx	Payments To Acquire Held To Maturity Securities Short Term PaymentsToAcquireHeldToMaturitySecuritiesShortTerm	22168000
	tgtx	Payments To Acquire Held To Maturity Securities Short Term PaymentsToAcquireHeldToMaturitySecuritiesShortTerm	71810000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	24333000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-33292000
	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	-975000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	46296000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1114000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	260000
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	25000000
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	125000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	72285000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-715000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5289000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-151812000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	103577000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	300151000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98288000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148339000
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97009000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147073000
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	1279000
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	1266000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98288000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148339000
	us-gaap	Interest Paid Net InterestPaidNet	3929000
	us-gaap	Interest Paid Net InterestPaidNet	2622000
	tgtx	Accrued Financing Costs AccruedFinancingCosts	1238000
	tgtx	Warrants Issued With Debt Financing WarrantsIssuedWithDebtFinancing	595000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13456358
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13512092
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13456358
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13512092
CY2023Q2	tgtx	Gross Net Accruals GrossNetAccruals	3800000
CY2023Q2	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	47896000
CY2023Q2	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	579000
CY2023Q2	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	47317000
CY2022Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	71778000
CY2022Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	1482000
CY2022Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	70296000
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	24000
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	29551000
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	659000
CY2023Q2	us-gaap	Inventory Net InventoryNet	30234000
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	243000
	tgtx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Interest Accrued Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings	286000
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-24000
CY2023Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	505000
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Share Based Compensation ShareBasedCompensation	1100000
CY2021Q4	tgtx	Paid In Kind Interest Rate PaidInKindInterestRate	0.0345
CY2023Q1	tgtx	Number Of Additional Advance Under Tranche NumberOfAdditionalAdvanceUnderTranche	2
CY2023Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0895
CY2023Q1	tgtx	Debt Instrument Paid In Kind Interest Rate DebtInstrumentPaidInKindInterestRate	0.0225
	tgtx	Debt Instrument Final Payment Fee On Other Advances DebtInstrumentFinalPaymentFeeOnOtherAdvances	0.0495
CY2023Q2	us-gaap	Other Long Term Debt OtherLongTermDebt	95000000
CY2022Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	70000000
CY2023Q2	tgtx	End Of Term Fee EndOfTermFee	9090000
CY2022Q4	tgtx	End Of Term Fee EndOfTermFee	6667000
CY2023Q2	tgtx	Long Term Debt Gross LongTermDebtGross	104090000
CY2022Q4	tgtx	Long Term Debt Gross LongTermDebtGross	76667000
CY2023Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	6390000
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	5532000
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	97700000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	71135000
CY2023Q2	tgtx	Long Term Debt Excluding Principal Payments LongTermDebtExcludingPrincipalPayments	97700000
CY2022Q4	tgtx	Long Term Debt Excluding Principal Payments LongTermDebtExcludingPrincipalPayments	71135000
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	97700000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	71135000
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	11300000
CY2023Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P2Y
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	552000
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	524000
	us-gaap	Operating Lease Cost OperatingLeaseCost	1096000
	us-gaap	Operating Lease Cost OperatingLeaseCost	1038000
CY2023Q2	us-gaap	Lease Cost LeaseCost	552000
CY2022Q2	us-gaap	Lease Cost LeaseCost	524000
	us-gaap	Lease Cost LeaseCost	1096000
	us-gaap	Lease Cost LeaseCost	1038000
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1512000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1581000
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9805000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10344000
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	11317000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	11925000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1188000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2388000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2100000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2080000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1913000
CY2023Q2	tgtx	Lessee Operating Lease Liability Payments Due Year Five And Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter	6543000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	16212000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4895000
CY2023Q2	tgtx	Operating Lease Liability Incremental Borrowing Rate OperatingLeaseLiabilityIncrementalBorrowingRate	11317000
	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001558370-23-013429-index-headers.html	Edgar Link	pending
0001558370-23-013429-index.html	Edgar Link	pending
0001558370-23-013429.txt	Edgar Link	pending
0001558370-23-013429-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tgtx-20230630.xsd	Edgar Link	pending
tgtx-20230630x10q.htm	Edgar Link	pending
tgtx-20230630xex10d1.htm	Edgar Link	pending
tgtx-20230630xex31d1.htm	Edgar Link	pending
tgtx-20230630xex31d2.htm	Edgar Link	pending
tgtx-20230630xex32d1.htm	Edgar Link	pending
tgtx-20230630xex32d2.htm	Edgar Link	pending
tgtx-20230630_def.xml	Edgar Link	unprocessable
tgtx-20230630_lab.xml	Edgar Link	unprocessable
tgtx-20230630_pre.xml	Edgar Link	unprocessable
tgtx-20230630x10q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
tgtx-20230630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TGTX
TG THERAPEUTICS, INC. Stock $tgtx

2023 Q3 Form 10-Q Financial Statement

#000155837023013429 Filed on August 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TGTX TG THERAPEUTICS, INC. Stock $tgtx

2023 Q3 Form 10-Q Financial Statement

#000155837023013429 Filed on August 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TGTX
TG THERAPEUTICS, INC. Stock $tgtx